Valsartan And Hydrochlorothiazide
Product Images NDC 53002-2787

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 53002-2787). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530022787)

Packaging label for Valsartan and Hydrochlorothiazide 320/12.5 mg tablets, containing 90 tablets. The label indicates the product is manufactured or distributed by RPK Pharmaceuticals, Inc. It includes dosing instructions and a barcode, along with placeholders for clinic and patient information.*

FDA Label Image

Figure-1 (Valsartan Hctz Figure 1)

A line chart showing the percentage of patients with systolic blood pressure (SBP) below 140 mmHg versus baseline SBP (140-180 mmHg) for four groups: Valsartan and Hydrochlorothiazide 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The Valsartan and Hydrochlorothiazide combination shows the highest percentage across baseline values, followed by Valsartan, Hydrochlorothiazide, and Placebo.*

FDA Label Image

Figure-2 (Valsartan Hctz Figure 2)

A line graph depicting the percentage of patients with diastolic blood pressure under 90 mmHg (% DBP<90) versus baseline diastolic blood pressure (mmHg). The graph compares the effects of Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo with distinct symbols for each treatment.*

FDA Label Image

Figure-3 (Valsartan Hctz Figure 3)

A line graph comparing the percentage of patients achieving systolic blood pressure (SBP) below 130 mmHg across baseline SBP values ranging from 140 to 180 mmHg. The graph shows data for Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo groups, indicated by different symbols.*

FDA Label Image

Figure-4 (Valsartan Hctz Figure 4)

A line graph comparing the percentage of patients achieving diastolic blood pressure (DBP) below 80 mmHg versus baseline DBP for four groups: Valsartan HCT 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and placebo. The x-axis represents baseline DBP values from 90 to 110 mmHg, and the y-axis shows the percentage of patients with DBP less than 80 mmHg.*

FDA Label Image

Hctz-stru (Valsartan Hctz Hydrochlorothiazide)

Chemical structure of the active ingredient in Valsartan and Hydrochlorothiazide, showing a detailed molecular diagram with labeled atoms and bonds.*

FDA Label Image

Valsartan-str (Valsartan Hctz Valsartan)

Chemical structure diagram of valsartan, part of the active ingredients in Valsartan and Hydrochlorothiazide by RPK Pharmaceuticals, Inc. The structure includes labeled atoms and bond arrangements typical for valsartan's molecular configuration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.